−1.72EUR
−19.72 MEUR
2.23 MEUR
2.35 M
About MAAT PHARMA
Sector
CEO
Hervé Affagard
Headquarters
Lyon
Website
Founded
2014
ISIN
FR0012634822
FIGI
BBG0131CZSZ6
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. It engages to restore and modulate patient-microbiome symbiosis to improve survival in cancer. The company develops microbiome drug candidates: Microbiome Ecosystem Therapies which are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. The company was founded by Herve Affagard, Joel Dore, Mohamad Mohty, Pierre Rimbaud and Pierre Belichard in 2014 and is headquartered in Lyon, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MAAT is 8.90 EUR — it has increased by 1.14% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange MAAT PHARMA stocks are traded under the ticker MAAT.
MAAT stock is 1.14% volatile and has beta coefficient of 0.74. Check out the list of the most volatile stocks — is MAAT PHARMA there?
Yes, you can track MAAT PHARMA financials in yearly and quarterly reports right on TradingView.
MAAT stock has fallen by 2.20% compared to the previous week, the month change is a 3.68% fall, over the last year MAAT PHARMA has showed a 8.44% decrease.
MAAT net income for the last quarter is −11.28 M EUR, while the quarter before that showed −8.44 M EUR of net income which accounts for −33.75% change. Track more MAAT PHARMA financial stats to get the full picture.
Today MAAT PHARMA has the market capitalization of 102.22 M, it has decreased by 4.75% over the last week.
No, MAAT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MAAT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MAAT PHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MAAT PHARMA technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MAAT PHARMA stock shows the buy signal. See more of MAAT PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MAAT PHARMA future price: according to them, MAAT price has a max estimate of 16.00 EUR and a min estimate of 15.00 EUR. Read a more detailed MAAT PHARMA forecast: see what analysts think of MAAT PHARMA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MAAT PHARMA EBITDA is −23.74 M EUR, and current EBITDA margin is −1.07 K%. See more stats in MAAT PHARMA financial statements.